Identifying heart risks in cancer patients after chemotherapy
Official title: Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity
Run by Mayo Clinic · NCT06353191 · Data updated 2026-11-12
This study is trying to find out why some cancer patients have heart problems after chemotherapy while others don't, by looking at their blood samples and medical records.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 693 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 4 sites (Scottsdale, Arizona and 3 other locations) |
| Status | Recruiting |
| Started | May 3, 2019 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | August 18, 2026 |
| Trial ID | NCT06353191 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who have received chemotherapy for any malignancy and either experienced cardiac toxicity or are at high risk for it.
✕Probably not a fit
Patients who are unable to understand the informed consent process will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to understand why some cancer patients experience heart function changes after chemotherapy while others do not. It involves collecting blood samples and reviewing medical records from patients who have developed chemotherapy-related cardiac toxicity and those at high risk for it. The study focuses on patients treated for various malignancies with different chemotherapy regimens, including immunotherapy and targeted therapies. By analyzing biospecimens, researchers hope to identify biomarkers that predict cardiac toxicity in these patients.
Why it matters
Potential benefit: If successful, this study could lead to better prediction and management of heart-related side effects in cancer patients undergoing chemotherapy.
How similar studies have gone: Other studies have explored similar approaches to understanding chemotherapy-related cardiac toxicity, indicating a growing interest in this area of research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy * One of the following: * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment * Completed chemotherapy with no cardiotoxicity at least two years post treatment * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity * An understanding of the protocol and its requirements, risks, and discomforts * The ability and willingness to sign an informed consent Exclusion Criteria: \- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Where it's running
-
Mayo Clinic in Arizona
Scottsdale, Arizona, United States Recruiting -
Mayo Clinic in Florida
Jacksonville, Florida, United States Recruiting -
Moffitt Cancer Center
Tampa, Florida, United States Recruiting -
Mayo Clinic in Rochester
Rochester, Minnesota, United States Suspended
Study contacts
- Principal investigator: Nadine Norton, PhD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if virtual informed consent methods help people decide to join cancer research
This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.
-
AI-powered supportive care chatbot for young adult cancer survivors
A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.
-
Telehealth pharmacist-led opioid education for cancer patients
This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.
-
Mindfulness program to help with symptoms in chronic graft-versus-host disease
A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.
-
Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors
This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.
-
Ambient sensor rooms to spot early problems in hospitalized cancer patients
This test will try whether special hospital rooms with cameras, microphones, and temperature sensors can help staff spot early delirium, falls, sleep problems, or mood changes in adults hospitalized with cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.